Sino-Biocan Overview
- Year Founded
-
2013
- Status
-
Private
- Employees
-
19
- Latest Deal Type
-
Series B
- Latest Deal Amount
-
$14M
- Investors
-
5
Sino-Biocan General Information
Description
Developer of the solutions designed for cell preparation tools. The company focuses on immune scientific research, systemic solutions for immune cell therapy as well as supporting technology and consumable management, providing clients with high-quality laboratory products.
Contact Information
Website
www.sinobiocan.comCorporate Office
- 2nd Floor, Building 15, No. 6055, Jinhai Road
- Fengxian District
- Shanghai, 201403
- China
Corporate Office
- 2nd Floor, Building 15, No. 6055, Jinhai Road
- Fengxian District
- Shanghai, 201403
- China
Sino-Biocan Valuation & Funding
| Deal Type | Date | Amount | Raised to Date | Post-Val | Status | Stage |
|---|---|---|---|---|---|---|
| 5. Later Stage VC (Series B) | 04-Mar-2024 | $14M | Completed | Generating Revenue | ||
| 4. Later Stage VC (Series A1) | 15-Jul-2022 | Completed | Generating Revenue | |||
| 3. Later Stage VC (Series A) | 28-Feb-2022 | Completed | Generating Revenue | |||
| 2. Later Stage VC | 28-Aug-2021 | Completed | Generating Revenue | |||
| 1. Early Stage VC | 21-Mar-2017 | Completed | Generating Revenue |
Sino-Biocan Patents
Sino-Biocan Recent Patent Activity
| Publication ID | Patent Title | Status | First Filing Date | Technology (CPC) | Citations |
|---|---|---|---|---|---|
| WO-2025035894-A1 | Cell fluid dispensing method | Inactive | 11-Aug-2023 | ||
| WO-2024187983-A1 | Centrifuge devices and separation methods using the centrifuge devices | Inactive | 13-Mar-2023 | ||
| WO-2024187683-A1 | Magnetic cell sorting | Inactive | 13-Mar-2023 | ||
| EP-4547819-A1 | Managing peripheral blood cells | Pending | 09-Aug-2022 | ||
| EP-4547819-A4 | Managing peripheral blood cells | Pending | 09-Aug-2022 | A61M1/3695 |
Sino-Biocan Signals
Sino-Biocan Investors (5)
| Investor Name | Investor Type | Holding | Investor Since | Participating Rounds |
|---|---|---|---|---|
| Dalton Venture | Venture Capital | Minority | ||
| Jinjue Investment Management | Growth/Expansion | Minority | ||
| Neovision Capital | Venture Capital | Minority | ||
| Grand Flight | Corporate Venture Capital | Minority | ||
| Sinovation Ventures | Venture Capital | Minority |
Sino-Biocan FAQs
-
When was Sino-Biocan founded?
Sino-Biocan was founded in 2013.
-
Where is Sino-Biocan headquartered?
Sino-Biocan is headquartered in Shanghai, China.
-
What is the size of Sino-Biocan?
Sino-Biocan has 19 total employees.
-
What industry is Sino-Biocan in?
Sino-Biocan’s primary industry is Therapeutic Devices.
-
Is Sino-Biocan a private or public company?
Sino-Biocan is a Private company.
-
What is Sino-Biocan’s current revenue?
The current revenue for Sino-Biocan is .
-
How much funding has Sino-Biocan raised over time?
Sino-Biocan has raised $21.8M.
-
Who are Sino-Biocan’s investors?
Dalton Venture, Jinjue Investment Management, Neovision Capital, Grand Flight, and Sinovation Ventures have invested in Sino-Biocan.
Data Transparency
-
Meet our data hygiene team
Discover how our experts ensure you’re getting the most accurate financial data in the industry.
Read more -
How PitchBook sources data
Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.
Discover our process